ASH 2017 | Results of the GMMG PERSPECTIVE trial: triple regimen for R/R multiple myeloma

Katja Weisel

Is the addition of cyclophosphamide to pomalidomide (Pom) and dexamethasone (Dex) treatment more effective at inducing a deeper and more durable remission for patients with relapsed and/or refractory multiple myeloma (MM) compared to Pom and Dex alone? Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, Katja Weisel, MD, of University of Tübingen, Tübingen, Germany, discusses the exciting results from the GMMG PERSPECTIVE trial (NCT02046915), which investigated this question.

Share this video